ACRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Aclaris Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.48+0.20 (+6.10%)
Close on Oct 19, 2026
- Market cap
- $496.72M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$1.58 (+83.16%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Aclaris Therapeutics, Inc. saw revenue fall 51.0% to $8.22M over the twelve months to Jun 30, 2026. Free cash flow was -$62.18M.
Revenue
$8.22M
-51.0% vs. a year earlier
Operating income
-$86.31M
TTM Q2 2026
Free cash flow
-$62.18M
TTM Q2 2026
EPS, diluted
-$0.58
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $496.72M
- P/E ratio
- –
- Price to sales
- 60.44
- Price to book
- 3.99
- Dividend yield
- –
- Free cash flow yield
- -12.52%
Fundamentals
- Revenue
- $8.22M
- Net income
- -$75.74M
- EPS, diluted
- -$0.58
- Free cash flow
- -$62.18M
- Book value per share
- $0.87
- Diluted shares
- 143M
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
$8.22M-51.0% YoY
Gross profit
$6.54M-54.6% YoY
Operating income
-$86.31M
Net income
-$75.74M
EPS, diluted
-$0.58
Free cash flow
-$62.18M
Reported periodTrailing twelve months